Log in

Relevant bibliographies by topics / 004.056.5; 57.087.2(043.2)

Contents

Journal articles

Academic literature on the topic '004.056.5; 57.087.2(043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '004.056.5; 57.087.2(043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "004.056.5; 57.087.2(043.2)"

1

Tsimberidou, A. M., C. Tam, W. Wierda, S. O' Brien, S. Lerner, and M. J. Keating. "Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7034.

Full text

Abstract:

7034 Introduction: High β2M levels are a risk factor in CLL. PCR therapy has been reported to be better tolerated than FCR in older or with decrease renal function pts (Shanafelt, Blood 108:15a). We assessed the association between age, CrCl, PS, β2M and outcomes in pts treated with FCR. Methods: From 7/99 to 1/04, 300 pts received rituximab 375 mg/m2 D1; fludarabine 25 mg/m2/d D2–3; and cyclophosphamide 250 mg/m2/d D2–3. Serum β2M levels were measured by radioimmunoassay. CrCl was calculated (Cockcroft-Gault equation). Results: The median age was 57 yrs (≥70, 14%). Age ≥70 was associated with

APA, Harvard, Vancouver, ISO, and other styles

2

Baron, Frederic, Myriam Labopin, Mohamad Mohty, et al. "Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT." Blood 114, no. 22 (2009): 3313. http://dx.doi.org/10.1182/blood.v114.22.3313.3313.

Full text

Abstract:

Abstract Abstract 3313 Poster Board III-201 RIC allo-SCT has been increasingly used as treatment for AML patients (pts) ineligible for myeloablative allo-SCT. Previous studies have observed a lower risk of relapse in pts who experienced chronic GVHD after RIC allo-SCT versus in those who did not. The objective of the current study was to further investigate the association between chronic GVHD and relapse in a large cohort of pts given RIC allo-SCT as treatment for AML. Data from 1188 AML pts in first or second CR transplanted between 2000 and 2008 following a RIC regimen at EBMT affiliated ce

APA, Harvard, Vancouver, ISO, and other styles

3

Willasch, Andre Manfred, Christina Peters, Petr Sedlacek, et al. "Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study." Blood 130, Suppl_1 (2017): 911. http://dx.doi.org/10.1182/blood.v130.suppl_1.911.911.

Full text

Abstract:

Abstract Introduction: Most pediatric patients (pts) with ALL receive total body irradiation (TBI) for myeloablative conditioning of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is unproven whether TBI can be replaced by chemotherapy (CHT). Methods: To compare the outcomes of TBI- versus (vs.) CHT-based conditioning, we performed a retrospective EBMT-registry based study. Children between 2 and 18 years of age (y.) after myeloablative conditioning for first allo-HSCT of bone marrow (BM) or peripheral blood SC (PBSC) from matched sibling (MSD) or unrelated donors (UD) in f

APA, Harvard, Vancouver, ISO, and other styles

4

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

5

Della Porta, Matteo G., Emilio Paolo Alessandrino, Andrea Bacigalupo, et al. "The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making." Blood 122, no. 21 (2013): 2765. http://dx.doi.org/10.1182/blood.v122.21.2765.2765.

Full text

Abstract:

Abstract Background The only curative treatment for patients with myelodysplastic syndrome (MDS) is allogeneic stem cell transplantation (allo-SCT). Decision to transplant is currently based on the International Prognostic Scoring System (IPSS), which has limitations. Recently, a revised IPSS (IPSS-R) has been developed (Blood. 2012;120:2454-2465). Aim To identify predictive factors for transplantation outcome, we studied 519 patients with MDS or acute myeloid leukemia (AML) evolving from MDS who received allo-SCT and were reported to the GITMO registry between 2000 and 2010. Results 1 Posttra

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Yu, and Xiao Jun Huang. "Donor Selection For Haploidentical Hematopoietic Stem Cell Transplantation: Who Is The Better – Donor-Recipient Risk Factor Analysis." Blood 122, no. 21 (2013): 705. http://dx.doi.org/10.1182/blood.v122.21.705.705.

Full text

Abstract:

Abstract Background many aspects should be considered when selecting an ideal donor. The progress made in haploidentical HSCT in recent years offers almost unlimited donor and availabilities of more than one donor at many occasions. To date, there have been no studies to answer the question of apart from HLA disparity, whether one donor should be preferred over another among various haploidentical donors available. The goal of the current study was to attempt to answer the question by analyzing the data on haploidentical HSCT without in-vitro T cell depletion modality. Methods Consecutive pati

APA, Harvard, Vancouver, ISO, and other styles

7

Kuendgen, Andrea, Michael Lauseker, Alan F. List, et al. "Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study." Blood 118, no. 21 (2011): 119. http://dx.doi.org/10.1182/blood.v118.21.119.119.

Full text

Abstract:

Abstract Abstract 119 Background: Lenalidomide (LEN) treatment resulted in RBC transfusion independence for ≥ 8 wks in 51–67% of patients (pts) and cytogenetic response in 25–73% of pts with lower-risk MDS and del5q in 2 large multicenter trials (MDS-003 and -004) (List A et al. NEJM 2006;355:1456–65; Fenaux P et al. Blood 2011; doi:10.1182/blood-2011-01-330126). However, these studies were either single-arm or allowed early crossover to LEN, thus data on the influence of LEN on AML progression and overall survival (OS) is lacking. Aims: To assess the risk of AML progression and death in LEN-t

APA, Harvard, Vancouver, ISO, and other styles

8

Nakayama, Y., R. Nakashima, T. Handa, et al. "POS1051 LUNG CLUSTERING ANALYSIS-BASED PHENOTYPES OF RHEUMATOID ARTHRITIS USING ARTIFICIAL INTELLIGENCE-BASED TECHNOLOGY FOR CHEST COMPUTED TOMOGRAPHY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 843.1–844. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2178.

Full text

Abstract:

BackgroundLung involvement is a prevalent extraarticular manifestation of rheumatoid arthritis (RA) that remains a significant clinical challenge. Few studies have comprehensively quantified lung abnormalities of RA patients using artificial intelligence-based (AI) technology.ObjectivesThe aim of this study was to quantify lung lesions in RA patients and classify them based on their lung parameters.MethodsAn AI-based quantitative computed tomography (CT) image analysis software (AIQCT) was applied to high-resolution CT scans of RA patients in a cross-sectional manner. AIQCT automatically class

APA, Harvard, Vancouver, ISO, and other styles

9

Lasa, Marta, Mario Nuvolone, Ioannis V. Kostopoulos, et al. "Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis." Blood 144, Supplement 1 (2024): 889. https://doi.org/10.1182/blood-2024-202995.

Full text

Abstract:

Background: Novel treatments targeting the plasma cell clone are increasing the rate of hematologic complete response (CR) and improving outcomes in AL amyloidosis. In multiple myeloma (MM), MRD negativity is considered the new CR and pivoted from a prognostic factor into a treatment endpoint and a surrogate for accelerated drug approval. By contrast, the role of MRD in AL amyloidosis remains uncertain and, accordingly, it is not routinely performed in clinical trials and practice. Aim: Investigate the clinical significance of MRD assessment in patients with AL amyloidosis. Methods: This multi

APA, Harvard, Vancouver, ISO, and other styles

10

Dörner, T., Y. Tanaka, M. Mosca, et al. "POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 639.1–639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2375.

Full text

Abstract:

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).ObjectivesTo assess the safety profile of BARI in patients with SLE.MethodsPatients with SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in one 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616964).ResultsA total of 1,849 patients were

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!